184 related articles for article (PubMed ID: 10520377)
1. [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].
Kreil A; Bauer J; Scheithauer W
Acta Med Austriaca; 1999; 26(3):93-100. PubMed ID: 10520377
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
4. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy studies with gemcitabine.
van Moorsel CJ; Veerman G; Bergman AM; Guechev A; Vermorken JB; Postmus PE; Peters GJ
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
Holcomb B; Yip-Schneider MT; Matos JM; Dixon J; Kennard J; Mahomed J; Shanmugam R; Sebolt-Leopold J; Schmidt CM
J Gastrointest Surg; 2008 Feb; 12(2):288-96. PubMed ID: 18049840
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines.
Whitehouse PA; Cooper AJ; Johnson CD
Pancreatology; 2003; 3(5):367-73; discussion 373-4. PubMed ID: 14526145
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment.
Schwarz RE; Donohue CA; Sadava D; Kane SE
Cancer Lett; 2003 Jan; 189(1):59-68. PubMed ID: 12445678
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content.
Bold RJ; Chandra J; McConkey DJ
Ann Surg Oncol; 1999; 6(3):279-85. PubMed ID: 10340887
[TBL] [Abstract][Full Text] [Related]
13. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells.
Pettersson F; Colston KW; Dalgleish AG
Pancreas; 2001 Oct; 23(3):273-9. PubMed ID: 11590323
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
16. 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Halloran CM; Ghaneh P; Shore S; Greenhalf W; Zumstein L; Wilson D; Neoptolemos JP; Costello E
J Gene Med; 2004 May; 6(5):514-25. PubMed ID: 15133762
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.
Bernhaus A; Ozsvar-Kozma M; Saiko P; Jaschke M; Lackner A; Grusch M; Horvath Z; Madlener S; Krupitza G; Handler N; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T
Invest New Drugs; 2009 Oct; 27(5):393-401. PubMed ID: 18841326
[TBL] [Abstract][Full Text] [Related]
18. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
[TBL] [Abstract][Full Text] [Related]
19. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines.
El Shafie RA; Habermehl D; Rieken S; Mairani A; Orschiedt L; Brons S; Haberer T; Weber KJ; Debus J; Combs SE
J Radiat Res; 2013 Jul; 54 Suppl 1(Suppl 1):i113-9. PubMed ID: 23824114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
